The hydrophobic integration based on sucralfate (SHIELD) is developed as a modular oral drug delivery platform for intestinal mucosa and nanoparticle delivery. SHIELD covers the entire gastrointestinal tract and can locally retain and preserve therapeutic nanoparticles, subsequently achieving complete excretion. When combined with CeO2 nanoparticles, SHIELD-CeO2 exhibits significant therapeutic effects in two different intestinal injury models: dextran sulfate sodium (DSS)-induced colitis and radiation-induced intestinal disease. This research was published under the title "Orally Administered Nanoparticle Coacervate for Therapeutic Coating of the Entire Gastrointestinal Tract" in Advanced Materials.
References: 
DOI: 10.1002/adma.202514708